Today: 9 June 2026
Browse Category

EPA:BNP.PA 9 October 2025 - 3 January 2026

Euronext Paris Shocks Markets with Historic Roots, Surging Stocks & Bold 2025 Moves

Auto Surge Can’t Save CAC 40: Paris Stocks Stall as Banks & Luxury Lag

The CAC 40 slipped 0.14% to 8,109.79 on November 3 as early gains faded. Autos outperformed, with Renault up 2.2% and Forvia jumping 5% on chip supply optimism, while BNP Paribas fell 1.6%. Capgemini dropped 2.8% after a cloud acquisition, and Hermès lost 1.5% on China demand concerns. France’s factory PMI rose to 48.8 but signaled continued contraction.
3 November 2025
······
Euronext Paris Shocks Markets with Historic Roots, Surging Stocks & Bold 2025 Moves

Euronext Paris Shocks Markets with Historic Roots, Surging Stocks & Bold 2025 Moves

Euronext Paris, Europe’s second-largest stock exchange, lists nearly 800 companies valued over $4.5 trillion and operates the CAC 40 index. The CAC 40 closed near 8,045 on October 8, 2025, up about 10% year-to-date but below its March peak. Euronext N.V. joined the CAC 40 in September amid strong IPO activity and political turmoil following the French Prime Minister’s resignation. Average daily turnover is €4.1 billion.
9 October 2025
·····

Stock Market Today

  • Aker BP Share Price Surges Amid Valuation Debate
    June 9, 2026, 11:54 AM EDT. Aker BP (OB:AKRBP) shares climbed to NOK347.7, marking a 55.05% total shareholder return over one year, outperforming peers in Norway's energy sector. Despite this momentum, the stock trades at an 8.6% premium over a fair value of NOK320.11, raising questions about valuation. The company aims to sustain production above 500,000 barrels per day past 2030, backed by projects like Yggdrasil and Johan Sverdrup, supporting revenue growth. Yet, potential risks include higher emissions costs and delays in key developments. Analysts offer cautious pricing, but a discounted cash flow (DCF) model from Simply Wall St suggests a much higher intrinsic value of NOK1,769.75, indicating significant undervaluation. Investors face a valuation divide between conservative targets and optimistic cash flow projections.

Latest articles

Paranovus Stock Rockets 620% as $195 Million Share-Sale Filing Changes the Story

Paranovus Stock Rockets 620% as $195 Million Share-Sale Filing Changes the Story

9 June 2026
Paranovus Entertainment shares soared 620% to $6.76 after filing to potentially sell up to $195 million in new stock—an amount far exceeding its $7.14 million market cap—raising major dilution risks for investors as the company eyes acquisitions but warns that future share sales could pressure the stock price or threaten operations.
Coupang Stock Gains as Privacy Ruling Approaches

Coupang Stock Gains as Privacy Ruling Approaches

9 June 2026
Coupang shares jumped 2% to $15.49, outperforming a falling market, as investors braced for South Korea’s privacy regulator to decide June 10 on possible sanctions over a data breach exposing 33.6 million records—a ruling that could trigger fines up to 3% of sales and impact the stock’s recovery.
AEP’s $78 Billion Grid Plan Spurs Data Center Hopes

AEP’s $78 Billion Grid Plan Spurs Data Center Hopes

9 June 2026
AEP lifted its five-year capital plan to $78 billion after signing 7 gigawatts of new large-energy project agreements, with 90% of 63 gigawatts of expected incremental load by 2030 tied to data centers; shares recently traded at $127.27, up 26.9% over 52 weeks, with analysts’ mean price target at $142.76, as investors weigh execution risks and a new data-center rate structure.
Dow climbs in New York, but gains may stall

Dow climbs in New York, but gains may stall

9 June 2026
Dow jumps 154.87 points as tech rebounds and oil prices drop, with chipmakers like Intel and Broadcom up sharply; investors brace for Wednesday’s key inflation data and next week’s Fed meeting, which could sway rate expectations and market direction.
U.S. Stocks Hit Records This Week — Why the S&P 500 and Nasdaq Rally Survived the Oil Shock

Dow Up While Nasdaq Dips; AI Rally Meets Inflation Data

9 June 2026
Nuvalent soared after GSK agreed to buy the cancer drug developer for $10.6 billion in cash, valuing shares at $124—a 40% premium to Monday’s close—while investors awaited Wednesday’s key inflation data that could impact market direction and tech stock stability.
Go toTop